The Institute of Biotechnology and Pharmaceutical Research (IBPR) emphasizes mission-oriented discovery and development novel therapeutics against cancers, metabolic diseases, infectious diseases, aging, rare diseases and prevalent local diseases. IBPR aims to engage in cutting-edge biomedical research for the improvement of health and quality of life for humanity. The representative accomplishments by IBPR are highlighted in several aspects below.

Scientific Innovation:

  • More than 610 peer-reviewed papers in prestigious international journals published since established
  • More than 188 patents granted since established
  • Seventeen new drug development candidates identified in the area of cancer, infectious diseases, pain control and metabolic diseases

Overview of IBPR new drug development candidates:

Stage of IBPR new drug development candidates:

Industrial Impacts:

Totally 6 cases (7 developmental drug candidates) of technology transfer to industry have been accomplished until July, 2020. There is 1 drug candidate, DBPR108, has been in the stage of Phase III, after the following pharmaceutical development by industry.

  • Anti-cancer drug candidates, DBPR104 and DBPR204 with all the IND-enabling studies completed, were transferred to a local pharmaceutical company (Sinphar Group) in 2008 and led to a start-up biotech company, SynCore Biotechnology Co. Ltd..  Pharmaceutical developments of DBPR104 and DBPR204 were conducted by SynCore with the names of SB01 and SB02, respectively. The IND (Investigational New Drug) application for SB01 was submitted to FDA and TFDA by SynCore in 2010 and approved for conduction of Phase I clinical trial, and then followed completion ofphase II clinical trial in 2019. This is the first model of new chemical entity domestically invented with relayed development through government, academic, research and industry cooperation.
  • Anti-diabetes drug candidate, DBPR108, was co-developed by IBPR and an industrial alliance composed of six domestic pharmaceutical companies and led by Genovate Biotechnology Co., Ltd.. IBPR and the alliance applied for a governmental grant as a “Case of Success” of biotechnology investment in Taiwan for DBPR108’s preclinical and phase I clinical trial studies. The single ascending dose and multiple ascending dose phase I clinical trials in humans were completed successfully in Taiwan in 2015. The China right of DBPR108 was transferred to Genovate Biotech in 2012 which then sub-licensed to China Shijiazhuang Pharmaceutical Group Co., Ltd. (CSPC), one of the major pharmaceutical companies in China, in 2013. CSPC’s IND application for Phase I clinical trial to CFDA (now called NMPA) has been approved in March 2015. Phase III clinical trials (single dose and multiple doses) in China started in the end of 2019 and are currently ongoing. This “Case of success” is unique in Taiwan with an aim to bring DBPR108 from bench to clinics under academia-industrial collaboration.
  • Anti-HCV drug candidate, DBPR110, was licensed to a local pharmaceutical company, Microbio, in 2013. Preclinical and pharmaceutical development of DBPR110 was conducted by IBPR and afterwards completed by Microbio with the name of MB-110. The IND application to FDA has been approved in Dec. 2015. DBPR110 is a potential therapeutic candidate for the treatment of HCV infection and of great market potential.
  • Anti-cancer drug delivery system, DBPR115, is a drug-conjugate candidate discovered and identified by IBPR in Dec. 2015. Through the collaboration with an US biotech company, Molecular Targeting Technologies Inc. (MTTI), a novel and specific delivery system for cancer therapeutics is developed as DBPR115. A local pharmaceutical company, Taivex, joined in the collaboration in Dec. 2015 and is helping to move DBPR115 toward the next major milestone of preclinical development and IND application.
  • Anti-cancer drug candidate, DBPR216, is a multi-targeted tyrosine kinase inhibitor that shows very good inhibitory effects on mutant c-KIT, FLT3, PDGFR kinases. It exhibits excellent growth inhibition against GIST and AML cell lines. DBPR216 was licensed to a local pharmaceutical company, Taivex, in Apr. 2019 and is helping to move DBPR216 toward the next major milestone of preclinical development.
  • Anti-cancer drug candidate, DBPR112, is a novel EGFR-TKI for NSCLC, which shows good inhibitory potential in the treatment of specific EGFR mutated lung cancers such as exon20 insertion (exon20INS). DBPR112 IND was approved by US and Taiwan Food and Drug Administration (FDA) in 2016. The Phase I clinical study was completed and reached a milestone which cooperation with National Taiwan University Hospital (NTUH) and Taipei Medical University Hospital (TMUH) during 2017-2018. DBPR112 was licensed to a local pharmaceutical company, AnBoGEN Therapeutics, in April 2020 for further clinical trial developments.

Social aspect:

  • Emergent actions to resolve the healthcare issues in Taiwan:
    -Synthesized grams scale amount of redemsivir, an approved drug to treat COVID-19 after the SARS-CoV-2 outbreak in early 2020.
    -Synthesized a sizable amount of oseltamivir (Tamiflu) during an influenza outbreak in 2005.
    -Identified two generic drugs which showed the inhibition of the SARS-CoV virus in 2003.
  • Working closely with domestic/international academics, research institutes, and industrial partners and fostering good collaborative spirits have led to acceleration of the R&D progress of novel drugs.
  • Cultivation of undergraduate/graduate students and postdoctoral fellows.
  • Students and fellows trained at IBPR, pursuing careers in industries, and government agencies, universities, have shown great impacts.
Share Button

Comments are closed.